When FLT3 inhibitors were first on the horizon, expectations were high, with hopes that they would have a similar level of efficacy to single agent treatments in other hematological malignancies. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Dr Stone provides a comprehensive overview of the expectations and results seen from treating acute myeloid leukemia (AML) patients with first-generation FLT3 inhibitors. Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, then discusses our increased understanding of these agents and how our use of them has evolved, with the development of second-generation FLT3 inhibitors, which often have multiple targets.
The story behind targeting FLT3 in AML and the next generation of inhibitors
